Verastem, Inc. (VSTM)

Market Cap	202.87M
Revenue (ttm)	n/a
Net Income (ttm)	-72.56M
Shares Out	200.86M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,076,159
Open	1.00
Previous Close	0.45
Day's Range	0.46 - 1.21
52-Week Range	0.29 - 1.47
Beta	0.79
Analysts	Strong Buy
Price Target	3.00 (+197.03%)
Earnings Date	May 9, 2023

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM

Financial Performance

In 2022, Verastem's revenue was $2.60 million, an increase of 26.45% compared to the previous year's $2.05 million. Losses were -$73.81 million, 3.67% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 197.03% from the latest price.

Price Target

$3.0

(197.03% upside)

Analyst Consensus: Strong Buy